A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 2904
Summary
- Conditions
- COVID-19
- SARS CoV-2 Infection
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 84 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04533399
- Collaborators
- Bill and Melinda Gates Foundation
- Investigators
- Study Director: Vivek Shinde, MD, MPH Novavax, Inc. Principal Investigator: Shabir A Madhi, MBBCH, PhD University of Witwatersrand, South Africa